Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 28:14:1149239.
doi: 10.3389/fendo.2023.1149239. eCollection 2023.

The crucial role and mechanism of insulin resistance in metabolic disease

Affiliations

The crucial role and mechanism of insulin resistance in metabolic disease

Xuefei Zhao et al. Front Endocrinol (Lausanne). .

Abstract

Insulin resistance (IR) plays a crucial role in the development and progression of metabolism-related diseases such as diabetes, hypertension, tumors, and nonalcoholic fatty liver disease, and provides the basis for a common understanding of these chronic diseases. In this study, we provide a systematic review of the causes, mechanisms, and treatments of IR. The pathogenesis of IR depends on genetics, obesity, age, disease, and drug effects. Mechanistically, any factor leading to abnormalities in the insulin signaling pathway leads to the development of IR in the host, including insulin receptor abnormalities, disturbances in the internal environment (regarding inflammation, hypoxia, lipotoxicity, and immunity), metabolic function of the liver and organelles, and other abnormalities. The available therapeutic strategies for IR are mainly exercise and dietary habit improvement, and chemotherapy based on biguanides and glucagon-like peptide-1, and traditional Chinese medicine treatments (e.g., herbs and acupuncture) can also be helpful. Based on the current understanding of IR mechanisms, there are still some vacancies to follow up and consider, and there is also a need to define more precise biomarkers for different chronic diseases and lifestyle interventions, and to explore natural or synthetic drugs targeting IR treatment. This could enable the treatment of patients with multiple combined metabolic diseases, with the aim of treating the disease holistically to reduce healthcare expenditures and to improve the quality of life of patients to some extent.

Keywords: NAFLD; T2DM; insulin resistance; metabolic disease; obesity.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Chronic metabolic diseases may be induced by IR.
Figure 2
Figure 2
(A) The insulin signaling pathway; (B) Abnormalities in the insulin signaling pathway caused by inflammatory cytokines, FFA, etc., involved in the development of IR.

Similar articles

Cited by

References

    1. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology (2005) 42(5):987–1000. doi: 10.1002/hep.20920 - DOI - PubMed
    1. Sharma VR, Matta ST, Haymond MW, Chung ST. Measuring insulin resistance in humans. Horm Res Paediatr (2020) 93(11-12):577–88. doi: 10.1159/000515462 - DOI - PMC - PubMed
    1. Muniyappa R, Madan R, Varghese RT. Assessing insulin sensitivity and resistance in humans. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, editors. Endotext. South Dartmouth (MA: MDText.com; Inc. Copyright © 2000-2021; MDText.com; Inc.; 2000. eng. - PubMed
    1. Gar C, Rottenkolber M, Prehn C, Adamski J, Seissler J, Lechner A. Serum and plasma amino acids as markers of prediabetes; insulin resistance; and incident diabetes. Crit Rev Clin Lab Sci (2018) 55(1):21–32. doi: 10.1080/10408363.2017.1414143 - DOI - PubMed
    1. Park SE, Park CY, Sweeney G. Biomarkers of insulin sensitivity and insulin resistance: Past; present and future. Crit Rev Clin Lab Sci (2015) 52(4):180–90. doi: 10.3109/10408363.2015.1023429 - DOI - PubMed

Publication types

Substances